Essentialis’ investigational compound DCCR has demonstrated a 30% to 40% reduction in triglyceride (TG) levels in a Phase 2b trial conducted with patients whose TG levels exceeded 500mg/dL.
DCCR is a crystalline salt of diazoxide, available in a controlled-release, once-a-day tablet formulation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In the Phase 2b double-blind, placebo-controlled study, half of the subjects were included in the atorvastatin combination sub-group and the remaining were in the monotherapy / fenofibrate combination subgroup.
Patients in the atorvastatin combination sub-group received either DCCR 290mg or placebo in combination with atorvastatin 20mg for 18 weeks, while those in the monotherapy / fenofibrate subgroup were randomised to receive either DCCR 290mg or placebo for 12 weeks, followed by co-administration of fenofibrate (Trilipix) 135mg for another six weeks.
DCCR 290mg in combination with statin resulted in placebo-adjusted median reductions of 28% in TG, 51% in very low density lipoprotein-cholesterol (VLDL-C), and 16% in non-high density lipoprotein-cholesterol (non HDL-C) levels with an increase in HDL-C of 11%, the study reported.
In combination with fenofibrate, DCCR showed median reductions in TG of 78%, in non-HDL-C of 34%, and an increase in HDL-C of 38%.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe study also showed that the increase in LDL-C was only 42% in the fenofibrate plus DCCR group when compared to 57% in the fenofibrate plus placebo group.
Following 18 weeks of treatment, DCCR demonstrated nearly a 40% improvement in HOMA-IR, a measure of insulin resistance, and a reduction in median weight of more than 3kg, compared to a worsening of HOMA-IR and no change in median weight in the placebo-treated subjects.
Essentialis president and chief executive officer Aaron D. Berg said: "Our plans to pursue next steps with DCCR are clear – we want to help patients reduce medical risks associated with very high triglyceride levels."
Essentialis board member and scientific advisory board head Richard Pasternak added: "These data clearly motivate us to advance DCCR into larger trials that may demonstrate benefit to patients with multiple disease risk factors."
Image: A crystalline salt of diazoxide has been found to show promise in a Phase 2b trial as monotherapy and in combination with existing lipid therapy. Photo: Benjah-bmm27
